ADMA BIOLOGICS INC (ADMA)
US0008991046 - Common Stock
ADMA gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. ADMA has an excellent financial health rating, but there are some minor concerns on its profitability. ADMA is not priced too expensively while it is growing strongly. Keep and eye on this one! This makes ADMA very considerable for growth investing!
1. Profitability
1.1 Basic Checks
ADMA had positive earnings in the past year.
In the past year ADMA had a positive cash flow from operations.
In the past 5 years ADMA always reported negative net income.
In the past 5 years ADMA reported 4 times negative operating cash flow.
1.2 Ratios
ADMA's Return On Assets of 17.44% is amongst the best of the industry. ADMA outperforms 98.41% of its industry peers.
ADMA has a better Return On Equity (29.38%) than 98.23% of its industry peers.
Looking at the Return On Invested Capital, with a value of 26.25%, ADMA belongs to the top of the industry, outperforming 99.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.44% | ||
| ROE | 29.38% | ||
| ROIC | 26.25% |
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 17.80%, ADMA belongs to the top of the industry, outperforming 96.81% of the companies in the same industry.
ADMA has a better Operating Margin (30.01%) than 98.76% of its industry peers.
ADMA's Gross Margin of 48.93% is fine compared to the rest of the industry. ADMA outperforms 77.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 30.01% | ||
| PM (TTM) | 17.8% | ||
| GM | 48.93% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
ADMA has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, ADMA has more shares outstanding
Compared to 5 years ago, ADMA has more shares outstanding
The debt/assets ratio for ADMA has been reduced compared to a year ago.
2.2 Solvency
An Altman-Z score of 16.83 indicates that ADMA is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 16.83, ADMA belongs to the top of the industry, outperforming 90.97% of the companies in the same industry.
The Debt to FCF ratio of ADMA is 1.29, which is an excellent value as it means it would take ADMA, only 1.29 years of fcf income to pay off all of its debts.
ADMA has a Debt to FCF ratio of 1.29. This is amongst the best in the industry. ADMA outperforms 95.40% of its industry peers.
ADMA has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
ADMA's Debt to Equity ratio of 0.44 is on the low side compared to the rest of the industry. ADMA is outperformed by 72.57% of its industry peers.
Even though the debt/equity ratio score it not favorable for ADMA, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 16.83 |
ROIC/WACC2.18
WACC12.05%
2.3 Liquidity
ADMA has a Current Ratio of 7.09. This indicates that ADMA is financially healthy and has no problem in meeting its short term obligations.
ADMA has a better Current ratio (7.09) than 68.32% of its industry peers.
A Quick Ratio of 3.26 indicates that ADMA has no problem at all paying its short term obligations.
ADMA's Quick ratio of 3.26 is in line compared to the rest of the industry. ADMA outperforms 41.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.09 | ||
| Quick Ratio | 3.26 |
3. Growth
3.1 Past
ADMA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 354.55%, which is quite impressive.
The Revenue has grown by 63.40% in the past year. This is a very strong growth!
ADMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 72.31% yearly.
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%
3.2 Future
ADMA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 68.38% yearly.
Based on estimates for the next years, ADMA will show a very strong growth in Revenue. The Revenue will grow by 29.20% on average per year.
EPS Next Y502.12%
EPS Next 2Y177.63%
EPS Next 3Y113.19%
EPS Next 5Y68.38%
Revenue Next Year64.69%
Revenue Next 2Y37.45%
Revenue Next 3Y34.44%
Revenue Next 5Y29.2%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 62.14, which means the current valuation is very expensive for ADMA.
Based on the Price/Earnings ratio, ADMA is valued cheaper than 94.16% of the companies in the same industry.
ADMA is valuated expensively when we compare the Price/Earnings ratio to 27.73, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 23.45, the valuation of ADMA can be described as rather expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ADMA indicates a rather cheap valuation: ADMA is cheaper than 93.98% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 22.83, ADMA is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.14 | ||
| Fwd PE | 23.45 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ADMA is valued cheaply inside the industry as 94.51% of the companies are valued more expensively.
ADMA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. ADMA is cheaper than 94.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 52.18 | ||
| EV/EBITDA | 33.53 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ADMA's earnings are expected to grow with 113.19% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.12
PEG (5Y)N/A
EPS Next 2Y177.63%
EPS Next 3Y113.19%
5. Dividend
5.1 Amount
No dividends for ADMA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ADMA BIOLOGICS INC
NASDAQ:ADMA (12/20/2024, 8:00:00 PM)
After market: 17.4 0 (0%)17.4
-0.5 (-2.79%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners78.63%
Inst Owner Change15.36%
Ins Owners2.27%
Ins Owner Change-0.91%
Market Cap4.11B
Analysts83.64
Price Target23.91 (37.41%)
Short Float %5.68%
Short Ratio3.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)36.22%
Min EPS beat(2)13.12%
Max EPS beat(2)59.31%
EPS beat(4)3
Avg EPS beat(4)-74.67%
Min EPS beat(4)-413.72%
Max EPS beat(4)59.31%
EPS beat(8)6
Avg EPS beat(8)-6.12%
EPS beat(12)8
Avg EPS beat(12)-3.82%
EPS beat(16)11
Avg EPS beat(16)-2.62%
Revenue beat(2)2
Avg Revenue beat(2)16.3%
Min Revenue beat(2)10.99%
Max Revenue beat(2)21.61%
Revenue beat(4)4
Avg Revenue beat(4)9.23%
Min Revenue beat(4)0.42%
Max Revenue beat(4)21.61%
Revenue beat(8)8
Avg Revenue beat(8)7.55%
Revenue beat(12)12
Avg Revenue beat(12)8.5%
Revenue beat(16)16
Avg Revenue beat(16)8.17%
PT rev (1m)23.4%
PT rev (3m)23.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)47.62%
EPS NY rev (1m)6.33%
EPS NY rev (3m)4.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)16.25%
Revenue NY rev (1m)4.01%
Revenue NY rev (3m)4.09%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 62.14 | ||
| Fwd PE | 23.45 | ||
| P/S | 10.74 | ||
| P/FCF | 52.18 | ||
| P/OCF | 47.8 | ||
| P/B | 17.74 | ||
| P/tB | 18.05 | ||
| EV/EBITDA | 33.53 |
EPS(TTM)0.28
EY1.61%
EPS(NY)0.74
Fwd EY4.26%
FCF(TTM)0.33
FCFY1.92%
OCF(TTM)0.36
OCFY2.09%
SpS1.62
BVpS0.98
TBVpS0.96
PEG (NY)0.12
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 17.44% | ||
| ROE | 29.38% | ||
| ROCE | 33.23% | ||
| ROIC | 26.25% | ||
| ROICexc | 35.04% | ||
| ROICexgc | 35.59% | ||
| OM | 30.01% | ||
| PM (TTM) | 17.8% | ||
| GM | 48.93% | ||
| FCFM | 20.59% |
ROA(3y)-17.8%
ROA(5y)-25.57%
ROE(3y)-38.32%
ROE(5y)-77.03%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.98
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.44 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 0.82 | ||
| Cap/Depr | 88.1% | ||
| Cap/Sales | 1.89% | ||
| Interest Coverage | 9.93 | ||
| Cash Conversion | 69.9% | ||
| Profit Quality | 115.69% | ||
| Current Ratio | 7.09 | ||
| Quick Ratio | 3.26 | ||
| Altman-Z | 16.83 |
F-Score8
WACC12.05%
ROIC/WACC2.18
Cap/Depr(3y)167.02%
Cap/Depr(5y)188.21%
Cap/Sales(3y)9.22%
Cap/Sales(5y)14.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)354.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%1400%
EPS Next Y502.12%
EPS Next 2Y177.63%
EPS Next 3Y113.19%
EPS Next 5Y68.38%
Revenue 1Y (TTM)63.4%
Revenue growth 3Y82.9%
Revenue growth 5Y72.31%
Sales Q2Q%78.13%
Revenue Next Year64.69%
Revenue Next 2Y37.45%
Revenue Next 3Y34.44%
Revenue Next 5Y29.2%
EBIT growth 1Y8410.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year768.46%
EBIT Next 3Y144.29%
EBIT Next 5Y89%
FCF growth 1Y179.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y200.53%
OCF growth 3YN/A
OCF growth 5YN/A